Tag Archives: Mylan

Competition Commission of India pulls up Roche for anti-competitive practices

Posted on April 27, 2017 by donttradeourlivesaway

By Jyotsna Singh, Scroll | April 27, 2017 In a landmark order, the commission has initiated an investigation into the multinational pharmaceutical company’s activities. The Competition Commission of India has initiated an investigation into Swiss pharmaceutical giant Roche for unfair … Continue reading →

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Tagged , , , | Leave a comment

CCI to investigate Swiss drugmaker Roche over breast cancer biosimilar

Posted on April 26, 2017 by donttradeourlivesaway

By Divya Rajagopal, The Economic Times | April 26, 2017 MUMBAI: The Competition Commission of India (CCI) will investigate Swiss drugmaker Roche over alleged attempts to block competitors from selling breast cancer drug Trastuzumab. The investigation has to be completed … Continue reading →

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Tagged , , , , | Leave a comment

Indian competition commission issues a path breaking order on abuse of dominant position in pharmaceuticals

Posted on April 25, 2017 by donttradeourlivesaway

Rules Roche’s practices prima facie appear to be aimed at blocking affordable biosimilar trastuzumab – a cancer drug – in India In July 2016, Mylan Pharmaceuticals and Biocon Limited approached the Competition Commission of India regarding Roche’s anti-competitive conduct to … Continue reading →

Posted in Anti competition, Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer | Tagged , , , , , | Leave a comment

Mylan is now Gilead’s branded medicine partner in India

Posted on January 31, 2014 by donttradeourlivesaway

Source: The Hindu MUMBAI, JAN 31: Gilead Sciences has expanded its alliance with fellow-multinational Mylan, by naming Mylan’s Indian subsidiary as its exclusive branded medicine partner for India. Mylan will market and distribute in India some of Gilead’s medications, a … Continue reading →

Posted in Voluntary License | Tagged , | Leave a comment

BMS demanda a Mylan (Matrix) Laboratories por vender versión genérica de medicamento VIH Atazanavir a OPS

Posted on August 9, 2012 by donttradeourlivesaway

(Previous published in English on August 3: BMS sues Mylan (Matrix) Labs for selling generic version of HIV drug Atazanavir to PAHO ) Bristol-Myers Squibb (BMS) ha presentado una queja de incumplimiento de contrato en contra de Mylan Laboratories en el … Continue reading →

Posted in Patents, Voluntary License | Tagged , , , , | Leave a comment

BMS sues Mylan (Matrix) Labs for selling generic version of HIV drug Atazanavir to PAHO

Posted on August 3, 2012 by donttradeourlivesaway

Bristol-Myers Squibb (BMS) has filed a breach of contract complaint against Mylan Laboratories in the US District Court, Southern District of New York. At the heart of the complaint is the procurement of the generic version of a HIV medicine … Continue reading →

Posted in Patents, Voluntary License | Tagged , , , | 1 Comment